Certain Inhalers Increase Risk of Respiratory Deaths

(Ivanhoe Newswire) -- A new study reveals one type of inhaler reduces the number of respiratory-related deaths, while the other actually increases the amount for patients with chronic obstructive pulmonary disease, an umbrella term for a number of respiratory diseases.

In an analysis of 22 trials, Cornell and Stanford researchers found the common bronchodilators known as anticholinergics (generically named tiotropium and ipratropium) reduced severe respiratory events by 33-percent and respiratory-related deaths by 73 percent compared to a placebo.

However, the inhaled beta-agonists such as metaproterenol sulfate (Alupent), formoterol (Foradil), salmeterol (Serevent, Advair) and albuterol (Proventil, Ventolin, Volmax and others) increased the risk of respiratory death by more than twice the amount compared to placebo. Researchers say most COPD patients are prescribed these inhalants.

Authors conclude, "These study results suggest that anticholinergics should be the bronchodilator of choice in COPD. The long-term safety of beta-agonists in patients with COPD should be addressed."

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.

SOURCE: Journal of General Internal Medicine, published online July 4, 2006